In recent years, immune checkpoint blockade (ICB) therapy,represented by molecules such as programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), h...In recent years, immune checkpoint blockade (ICB) therapy,represented by molecules such as programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has made revolutionary progress in the field of tumor treatment. However, the efficacy of ICB in different clinical cancer patients varies greatly, with most patients showing little or no response to the treatments [1]. The suppressive tumor immune microenvironment (TME) containing high myeloid cells is a major cause of the failure of immunotherapy[2,3].展开更多
基金National Natural Science Foundation of China (12375334)Key Program of Wenzhou Institute, University of Chinese Academy of Sciences (WIUCASQD2021015)。
文摘In recent years, immune checkpoint blockade (ICB) therapy,represented by molecules such as programmed cell death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has made revolutionary progress in the field of tumor treatment. However, the efficacy of ICB in different clinical cancer patients varies greatly, with most patients showing little or no response to the treatments [1]. The suppressive tumor immune microenvironment (TME) containing high myeloid cells is a major cause of the failure of immunotherapy[2,3].
